Jasper Therapeutics Reports Preliminary Data From Ongoing SPOTLIGHT Phase 1b/2a Study Of Subcutaneous Briquilimab; Says 14 Of 15 Participants Enrolled Achieved Clinical Response
Portfolio Pulse from Benzinga Newsdesk
Jasper Therapeutics reported promising preliminary data from its SPOTLIGHT Phase 1b/2a study of Briquilimab, with 93% of participants achieving a clinical response. The drug was well tolerated, and Jasper plans to expand the study with a higher dose cohort. Full data is expected in 2025.
October 14, 2024 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jasper Therapeutics' Briquilimab shows promising results in the SPOTLIGHT study, with 93% of participants achieving a clinical response. The drug was well tolerated, and the company plans to expand the study with a higher dose cohort.
The high clinical response rate and absence of serious adverse events are positive indicators for Briquilimab's potential. The regulatory clearance for a higher dose cohort suggests confidence in the drug's safety and efficacy, likely boosting investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100